Dr. Thomas Adriano McInnes Lazzarini, MD

Dr. Lazzarini practices at Merton Suzuki MD Inc in Poway, California.

Dr. Lazzarini's NPI, 1477088979, was assigned on April 22, 2017. Dr. Lazzarini graduated from Yale School of Medicine in 2017. Dr. Lazzarini's California license number on file is A191729.

Dr. Lazzarini's primary practice is Merton Suzuki MD Inc, at 12630 Monte Vista Rd, Poway, CA 92064 in San Diego County. The practice phone is (858) 487-6860.

Dr. Lazzarini's primary practice is Merton Suzuki MD Inc in Poway, California. Dr. Lazzarini is also affiliated with Scripps Memorial Hospital La Jolla. Dmand AI also links Dr. Lazzarini to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lazzarini practices, 2 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Lazzarini's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Lazzarini is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Lazzarini's licenses on file in 2 states: California and Florida.

Dmand AI lists age-related macular degeneration, cataract, glaucoma, retinal detachment, surgical retina and vitreous procedures and vision problems among the conditions Dr. Lazzarini treats.

CMS data shows 6,491 Medicare services from Dr. Lazzarini across 14 procedure codes in 2024, for 391 Medicare patients. Medicare paid $384,884 for them.

CMS counts 391 Medicare patients who saw Dr. Lazzarini in 2024. The largest group is 65 to 74, with 163 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lazzarini's median patient age at 62, with 53% women.

In 2024, Dr. Lazzarini wrote 318 Medicare Part D claims for 121 patients. 74% of them were for generic drugs. CMS names the drug for 255 of them, across 7 drugs with 11 or more claims each, at $4,539 in total drug cost. In 2023, CMS named 482 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Lazzarini for performance year 2024, reported as part of a group. Dr. Lazzarini accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 20 papers to Dr. Lazzarini, published from 2012 to 2023. 2020 was the busiest year, with 8. The most frequent topics are COVID-19, Retinal Diseases and Tomography, Optical Coherence. Dr. Lazzarini has published most often in Ophthalmic Genet. Dr. Lazzarini's most frequent co-authors are Hasenin Raid Hashim Al-Khersan, MD, Kenneth Chen Fan, MBA, MD and Jayanth Srinivasan-Kasi Sridhar, MD.

CMS Open Payments shows 82 general payments to Dr. Lazzarini from 11 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 54% of the total. Abbvie Inc. paid the most, $7,874.

Dr. Lazzarini graduated from Yale School of Medicine in 2017.

Dr. Lazzarini is in network with 18 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.